Nanomedicines, since the approval of the first one in the 1950s, have been accompanied by expectations of higher efficiency and efficacy, compared to less complex drugs. The fulfilment of those expectations has been slower than anticipated, due to the high complexity of nanomedicine drugs combined with a lack of scientific understanding of nanomedicine interactions with biological systems. The unique properties of their size and their surface composition create difficulties in their physicochemical characterization, and as a consequence, difficulty in assessing the similarity of follow-on products (nanosimilars) to originator nanomedicines. During the 2018 European Federation for Pharmaceutical Sciences (EUFEPS) annual meeting "Crossing the barrier for future medicines" in Athens, there were several sessions on nanomedicines organised by the EUFEPS Nanomedicine Network. This review focuses on the session "Nanomedicines and nanosimilars: how to assess similar?", discussing the nature of nanomedicines, the regulatory aspects of the topic and the impact of practical use and handling of such medicinal products. Emphasis is put on the consequences their nanosize-related properties have on the establishment of their critical quality attributes and how this affects the demonstration of bioequivalence of nanosimilars to their originator products. The lack of an appropriate and harmonized regulatory evaluation procedure and the absence of corresponding education are also discussed, especially the uncertainty surrounding the practical use of nanosimilars, including the higher healthcare cost due to less than satisfactory number of safe and efficacious nanosimilars in the market.
Introduction
Over the recent years, there has been a steady increase in the number of publications on the topic of nanomedicines. As of August 2018, PubMed returns 20,663 results to the search term 'nanomedicine'. Publications in the field currently focus more on safety and efficacy. There is also a high number of clinical trials that include the term 'nano' listed as actively recruiting or active on ClinicalTrials.gov. The regulatory bodies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have engaged the scientific community and industry stakeholders via different guidance documents. In May 2018, at the European Federation for Pharmaceutical Sciences (EUFEPS) annual meeting "Crossing Barriers for Future Medicines" in Athens (Greece), several sessions on nanomedicines were organised by the EUFEPS Nanomedicine Network. This review will focus on the session "Nanomedicines and nanosimilars: how to assess similar?" dedicated to regulatory aspects of the topic, in addition to the impact of practical use and handling of such medicinal products. We aim to cover the content of this session here, with the addition of necessary background information.
Nanomedicines: terms and definitions
The EMA defines nanotechnology as 'the production and application of structures, devices and systems by controlling the shape and size of materials at nanometre scale'. The nanometre scale ranges from the atomic level at around 0.2 nm (2 Å) up to around 100 nm (EMA, 2006) , which is disregarding the fact that many nanomedicines are of considerably larger size. This is the base for the EMA's working definition of what a nanomedicine is: 'Nanomedicine is defined as the application of nanotechnology in view of making a medical diagnosis or treating or preventing diseases. It exploits the improved and often novel physical, chemical and biological properties of materials at nanometer scale' (EMA, 2006) . Hence, nanomedicines are designed to provide physicochemical and biological properties, which are attributable to their size and surface morphology, making them distinct from low molecular weight drugs. The rationale of the development of such products is manifold and includes the improvement of drug delivery, for example by controlled and/or site-specific drug release, or improved drug transport across biological barriers, which otherwise would not be accessible (Ventola, 2012) .
There are many different types of nanotechnology in use for medicinal products. The most common ones are liposomes, nanocrystals, emulsions and iron-carbohydrate complexes, which make up more than three-quarters of nanomedicines presently in clinical use (D'Mello et al., 2017) . Besides cancer therapy, nanomedicines are applied in many other therapeutic areas, including inflammatory diseases, infections and anaemia (D'Mello et al., 2017) . Nanomedicines may also be classified according to the various routes of administration ranging from oral to topical to parenteral. In this article we will focus only on intravenously (IV) administered nanomedicines, as this was also the focus of the session at the EUFEPS meeting. In the FDA's recently published draft guidance, these products are identified as high risk and are likely to 'exhibit clinically significant changes in exposure, safety, and/or effectiveness relative to the referenced product ' (FDA, 2017) .
For most drug products containing nanomaterials, the active substance is not a homo-molecular structure (Lygature Website; Schellekens et al., 2014) . Much like complex biological products such as therapeutic proteins and monoclonal antibodies, their structure often consists of different, closely-related structures that cannot be isolated and fully quantitated, characterized, and/or described by physicochemical analysis (Lygature Website; Schellekens et al., 2014) . Being of synthetic ("non-biologic") nature, nanomedicines fall under the class of non-biological complex drugs (NBCDs), as defined by the NBCD working group (Lygature Website). While the two major western regulatory bodies, the FDA and the EMA, are recognising the complexity of these products, they take different approaches in evaluating nanomedicine products and their follow-ons, or nanosimilars, as they are also known (Ehmann et al., 2013; .
There have been many publications exploring structure-activity relations of the physicochemical characteristics of nanomedicines, yet as of today it remains unclear if they are clinically meaningful to the patient, or in fact whether all relevant characteristics have been identified yet (Di Francesco et al., 2017; Schellekens et al., 2011; Fornaguera and Solans, 2017) . Nevertheless, attributes such as structural qualities that relate to function, surface properties (e.g., surface area, surface charge, chemical reactivity, ligands, hydrophobicity, and roughness), coating properties, porosity (if it relates to a function, e.g., capacity to load a drug), particle concentration and size range, in vitro release, crystal or amorphous form, impurities, sterility and endotoxin levels, have been put forward as good candidates (Di Francesco et al., 2017) . All these properties may influence the pharmacokinetic (PK) and pharmacodynamic (PD) properties including their toxicity profile (Di Francesco et al., 2017) . This difficulty in identifying the critical quality attributes (CQAs) has led to an ongoing scientific discussion.
The realities of nanomedicines
The number of nanomedicine approvals shows an increasing trend in the US (D'Mello et al., 2017) , with many more products in clinical trials or at other stages of the approval progress (Di Bobo et al., 2016 ). An overview of parenteral nanomedicines currently available in the market, are listed in Table 1 . Some of the most successful and well-established ones include AmBisome® (liposomal amphotericin B), Caelyx®/Doxil® (liposomal doxorubicin), Copaxone® (glatiramer acetate, a synthetic polypeptide), Venofer® (iron sucrose, a nanoparticular polymeric iron-carbohydrate) and Abraxane® (albumin-bound paclitaxel).
Liposome-based nanomedicines are composed of naturally derived phospholipids, are coated with polyethylene glycol (PEG) and are biodegradable (Akbarzadeh et al., 2013) . They are generally non-immunogenic, thus allowing for a better toxicity profile (Akbarzadeh et al., 2013) . Additionally, molecule PEGylation has been shown to increase half-life and decrease plasma clearance, allowing for better stability and longer circulation time in the bloodstream (Akbarzadeh et al., 2013) . As a result, PEGylated liposomes are increasing the incorporated drug's systemic availability and consequently, the treatment window by extended and increased drug exposure (Akbarzadeh et al., 2013) .
AmBisome®, the first liposomal nanomedicine approved by the EMA, is able to bind to fungal cell walls, where the liposome with the incorporated amphotericin B is disrupted (Adler-Moore and Proffitt, 2008) . Amphotericin B can remain bioavailable for several weeks following the initial treatment (Adler-Moore and Proffitt, 2008) . It has been proven to have a better safety profile than the conventional amphotericin B solution with respect to infusion-related toxicity and nephrotoxicity, while maintaining the same efficacy in patients (AdlerMoore and Proffitt, 2008; Azanza et al., 2015) . AmBisome®'s advantages are specific to this drug product, while other liposomal amphotericin B drug products do not show the same safety and efficacy profile (Azanza et al., 2015) . This also demonstrates the importance of the specific composition and the corresponding manufacturing process.
Liposomal doxorubicin was approved in the EU as Caelyx® and as Doxil® in the US, where it was the first nanomedicine to be approved by the FDA. It has demonstrated a more favourable toxicity profile than conventional doxorubicin, with better cardiac tolerance and less myelosuppression, alopecia, nausea and vomiting (Rafiyath et al., 2012) . It is common for nanomedicines to allow for the use of efficacious molecules that otherwise could not be used because of their high toxicity and other safety issues (Akbarzadeh et al., 2013) .
The potential ability of targeting specific organs and tissues can be a potential game-changer. For the indication of Kaposi's sarcoma (KS), Caelyx®/Doxil® allows for preferential release at KS lesions reducing general toxicity (James et al., 1994) through the so-called enhanced permeation and retention (EPR) effect (Wong et al., 2015) . In the field of neurodegenerative diseases, the ability of nanomedicines to cross the blood-brain barrier and target specific central nervous system regions could change patient disease progress and quality of life significantly (Poupot et al., 2018) . In cancer therapy, the most beneficial effect is the higher permeation by passive diffusion and carrier accumulation in the region of the tumour, due to a high concentration gradient between the blood vessels and the tumour microenvironment. Thus we can see that nanomedicines can excel in the combination of multiple mechanisms of drug targeting and drug actions.
The reduction of side effects by improving the PK and specific (passive/active) targeting are major advantages of nanomedicines. Nevertheless, due to their unique characteristics, they might also have different side effects, as observed for instance with Caelyx®/Doxil®. The PEG coating, which has been used to instil desirable characteristics can also impact the PK and PD of nanomedicines in a negative way, sometimes resulting in new, different adverse effects. For example, palmar plantar erythrodysesthesia can occur more often with Caely®/ Doxil®, due to preferential concentration in the skin because of the polyethylene glycol coating (Lorusso et al., 2007) . This limits the maximum dose of drug that can be administered (Lorusso et al., 2007) .
Abraxane® is a drug product consisting of nanoparticles formed from albumin-bound paclitaxel, which shows increased blood retention time and increased bioavailability, when compared to the free drug (Sofias et al., 2017) . It is better tolerated in women with breast cancer than conventional paclitaxel, as patients to be treated with Abraxane® do not need pre-treatment with drugs to prevent hypersensitivity reactions (Vishnu and Roy, 2011) . In addition, it has shown better efficacy than conventional paclitaxel-containing drugs in patients with metastatic breast cancer, whose first treatment was no longer efficient. This allowed Abraxane® to have a different label indication, compared to conventional paclitaxel (Ciruelos and Jackisch, 2014). Nanocolloidal solutions of iron carbohydrates for intravenous applications are another example of frequently used nanomedicines. The first nanotechnology-based intravenous iron product was introduced in the 1950s, and is now known as Venofer®. To overcome the high toxicity of iron (II) salts, iron in the form of polynuclear Fe(III)-oxyhydroxide core stabilized by a carbohydrate shell was developed (Mühlebach and Flühmann, 2015) . Intravenously-applied Venofer® nanoparticles have been shown to be tolerated at more than 20-fold higher 50% lethal dose (LD 50 ) levels, compared to iron sulphate solutions in mice (Geisser et al., 1992) . After administration, the iron carbohydrate particles interact with the innate immune system for uptake and release of bioavailable iron (Koskenkorva-Frank et al., 2013; Geisser and Burckhardt, 2011) . It is assumed that the characteristics of the nanoparticles affect the fate and disposition in the body (Toblli et al., 2009a; Toblli et al., 2009b; Toblli et al., 2012; Toblli et al., 2015; Toblli et al., 2017) . There is a plethora of evidence showing that iron sucrose follow-on products from different manufacturers have different efficacy and safety profiles despite most of them complying with the USP monograph quality requirements (Rottembourg et al., 2011; Agüera et al., 2015; Lee et al., 2013) . Since the CQAs are not fully understood, the manufacturing process defines the product, and is crucial for the consistency and quality of the end product, and its clinical performance . A robust manufacturing procedure needs to be in place and thoroughly sustained in order to ensure batch-to-batch consistency.
Regulatory challenges: the EU perspective
The properties and characteristics, including the CQAs of nanomedicines have made the process of development and the consistency of manufacturing very challenging. This applies also to their follow-on products (Ehmann et al., 2013; Marden et al., 2018) . Minor changes in manufacturing may lead to unknown changes of the product composition, which can affect the clinical performance. Hence, the manufacturing defines the product. Based on existing approval pathways, a follow-on can be approved by the EMA in an abridged application process as a generic or as a hybrid [articles 10(1) and 10(3), respectively] (Fig. 1) . The scientific community, the pharmaceutical industry and the EMA have acknowledged that it is indeed scientifically challenging to demonstrate sameness of a follow-on nanomedicine to a reference (originator) drug. Due to their complexity, the generic "sameness" approach was deemed invalid for nanomedicines and the term "nanosimilar" was suggested instead (Ehmann et al., 2013; . The challenges can be described by the equation used to demonstrate therapeutic equivalence (TE) of generics: PE + BE = TE, where PE is the pharmaceutical equivalence and BE is the degree of bioequivalence of two drugs. The definition of PE means in essence the presence of the same active ingredients in the same composition. As indicated above for many nanomedicines, the active substance is not a homo-molecular structure, but rather consists of different, closely-related, nanoparticulate structures that cannot be isolated and fully quantitated, characterized, and/or described by physicochemical analytical means (Lygature Website; Schellekens et al., 2014) . Nanomedicines are often designed with the intention of altering the pharmacokinetic and/or pharmacodynamic properties of the parenteral drug substance. Therefore, they cannot be considered simply a formulation, as the entire drug product is responsible for its in vitro and in vivo (PK/ PD) profile; hence, the drug product must be considered as the drug substance. Currently, for many nanomedicines, the structure-function relation is not fully understood. Thus, defining the clinically meaningful CQAs remains a challenge. In the absence of conclusive CQAs, it is impossible to know, which parameters should be characterized for the demonstration of sameness. Additionally, PE implies that the two products should clearly show, in addition to the originator's physicochemical profile, the same strength, dosage form and route of administration, as well as comparable labelling. BE can be shown by determining the PK/PD profile, through in vitro, in vivo, pre-clinical and clinical studies. For nanomedicines, this is complicated by the fact that nano-characteristics affect the bio-distribution and targeting, which cannot be addressed by a plasma drug profile only. The absence of harmonized approval processes for nanomedicines in the EU and elsewhere has been addressed by the different stakeholders, including the NBCD working group (Lygature Website), and progress has been made throughout the European Union (Hussaarts et al., 2017) . During the years 2011-2015, reflection papers on the data requirements for nanosimilars of IV iron-based nano-colloidal originator products were issued (EMA, 2011; EMA, 2013; EMA, 2015) . The EMA does recognise that in vivo studies for such products may be required to demonstrate bioequivalence or comparable distribution and targeting pattern of a nanosimilar to its originator or reference product during the different stages of development, or during comparability studies (EMA, 2015) . Whereas in Europe there is an agreement that the demonstration of sameness is scientifically challenging and the generic pathway 10(1) is not appropriate (EMA, 2011; EMA, 2013; EMA, 2015) , different opinions exist as to whether the EU legislation is truly ready for the evaluation and regulation of non-biological complex drugs (Ehmann, 2016; De Vlieger et al., 2016) . Ehmann makes the point that with the hybrid pathway 10(3), the European legislation offers a suitable and flexible regulatory pathway for the approval of follow-on nanomedicines. On the other hand, de Vlieger et al. argue for the need of a pathway inspired by the biosimilar pathway, based on similarity demonstration, the step-wise approach and the principles of totality of evidence. Fig. 2 illustrates the basis of the latter groups' argument.
Pharmacovigilance (PV) as a method to detect signals after market approval, is another challenge with nanosimilars. Reports of adverse effects usually state only the international non-proprietary name (INN), rather than the brand name, making it impossible to correctly associate an adverse effect with the responsible product (originator or nanosimilar). Requesting the brand name, in addition to the INN in safety reports is suggested to lead to effective safety monitoring of both originator products and their nanosimilars (Borchard et al., 2012) .
Despite all the evidence that supports the non-substitutability of nanosimilars, there are no means of protecting the patient, other than through pharmacist and physician education on the specifics of nanomedicines with a focus on their selection and practical use (Astier et al., 2017) . This is due to the absence of an official standard regarding approval withdrawal of such follow-on versions, which is in contrast to innovator drugs and the established post-marketing surveillance. On the other side, nanosimilar manufacturers are left without clear guidance on how to achieve approval and without an indicated stepwise approach, which can be followed in the production of a solid drug product ultimately for the benefit of the patient. Although the EMA is to be commended for publishing science-based guidance on the topic, there is still a lot of work to be done to fill the gap of scientific understanding. The EMA still needs to align with state-of-the-art knowledge and exchange with experts externally to discover and adapt the methods of evaluating a nanosimilar to the realities of the market for the protection of the patient and their therapeutic benefit.
Formulary selection, handling and use
The complex nature of nanomedicines becomes even more apparent, when the hospital formulary selection process by hospital pharmacists is considered, in addition to how nanomedicines are handled and used by health care professionals (HCPs). From the lack of appropriate PV to the lack of a streamlined, tailor-made regulatory approval pathway, HCPs are in a difficult position. In addition, there is evidence showing lack of education (Knoeff et al., 2018) .
A recent study revealed limited awareness of the specific defining characteristics of nanomedicines (Knoeff et al., 2018) . 70 HCPs in France and 70 HCPs in Spain were interviewed via an online questionnaire, to assess their formulary selection and dispensing behaviour of intravenous iron drug products. The results conclusively pointed towards a decision-making process that only considers costs, rather than being based on scientific data (Knoeff et al., 2018) . It is also very alarming to see that, since previously these products were approved as generics, healthcare professionals consider originators and nanosimilars of intravenous iron products to be fully interchangeable, without taking into consideration the different safety and efficacy profiles previously demonstrated (Fig. 3) . The decision of which drugs will be dispensed, is often taken by the hospital pharmacist, and should be guided by European Journal of Pharmaceutical Sciences 128 (2019) 73-80 scientific knowledge acquired on the peculiarities of nanomedicines (Knoeff et al., 2018) . The lack of general awareness of the unique properties of nanomedicines can have additional detrimental effects on the patient. As nanomedicines require adherence to very strict handling, storage and administration protocols, failure to do so can lead to multiple negative implications for the patient. As an example, non-optimal dilution can lead to adverse effects caused by instability of the product (Lee et al., 2013) . Transport and storage temperature, use of appropriate solvent and dilution, and the speed of administration are very important for the safety and efficacy of a nanomedicine.
HCPs, in particular hospital pharmacists, should take the initiative to be educated on nanomedicines and take on the responsibility of being the experts on the subject in their workplace. Practically, they can apply their acquired knowledge of the unique physicochemical properties of this drug category to ensure the safe and efficacious use of nanomedicines. They should also judge the comparability of nanosimilars and actively influence the formulary decision-making process, by educating their fellow HCPs on their unique characteristics. This in turn, will ensure the appropriate storage (light and temperature), handling and administration (including appropriate dilution and dosage) of these products. Finally, they should be very vigilant in monitoring and reporting adverse effects, as well as interactions with other drugs.
The scientific community has rallied behind HCPs and specifically hospital pharmacists with a lot of publications on the topic. A comprehensive report that is discussing all relevant selection criteria that should be applied when choosing a nanosimilar for a hospital formulary has been published recently (Astier et al., 2017) . The regular selection criteria have been expanded to include nano-specific criteria, which take into consideration the nature of nanomedicines and their unique pharmaceutical, safety and efficacy profiles (Fig. 4) . In Fig. 4 , the text highlighted in red depicts those distinctive characteristics, such as particle size and size distribution, particle surface characteristics and uncaptured pharmacological active moiety. As mentioned before, not all nanosimilars are created equal, especially due to the fact that their approval followed a non-specific and non-uniform approval pathway. Additionally, the publication includes a comprehensive list of questions to ask when evaluating nanomedicines and their nanosimilars for formulary inclusion, which can further assist this complicated and multidimensional selection process.
Impact on access and cost
Spending for intravenous nanomedicines in 2016 was EUR 1.47 billion in EU-5 (France, Germany, Italy, Spain and the UK), and USD In a simulation model, the potential savings that could be realized in EU-5 countries and the US, if an appropriate regulatory pathway for granting nanosimilars market access were in place, were estimated.
Considering that i) the generic pathway and price model is not applicable to nanosimilars, and that ii) potential manufacturers have to have development capabilities similar to manufacturers of biologics, the applied model is based on the premise that data on the market access of, and savings with, biosimilars can be extrapolated to the nanosimilar market. The analysis used data from the biosimilar market and applied them appropriately to nanosimilars. Although it remains to be seen whether the development of the nanosimilar market will reflect that of the biosimilar market, the strength of this model is its foundation on real-world market data.
The model used is based on the average price reduction of biologics across the EU-5 countries only, as the development in the US, where the first biosimilar (Zarxio, filgrastim, Sandoz Inc) was only introduced in March 2015, is still unknown (Raedler, 2016) . This biosimilar was offered at a 15% discount to the reference list price (Avalere Health, 2016) , which is slightly less than the average price decrease of biologics in the EU-5, but still within the observed range. Conversely, potential savings may be underestimated as undisclosed payer-specific discounts were not considered (or imputed) in the model.
Our model took into account that a lower price in the off-patent nanomedicine market arises from not only less expensive nanosimilars, but also the repricing of the reference nanomedicines to remain competitive; this reflects the experience in the off-patent biologics market. Potentially increased sale volumes driven by the lower prices of biosimilars were not taken into account in our forecast model of nanomedicines cost [introduction of biosimilars likely gave broader access to therapy with biologic drugs (IMS Health, 2016) ]. However, even if a part of the saved spending for nanomedicines is consumed by an increase in prescriptions, it would remain a societal gain by providing more patients access to treatment (Garattini and Padula, 2017) .
The predicted savings potentials for the EU-5 and the US in year 2020 are EUR 280 million and USD 2.00 billion, respectively (Fig. 5) . The long-term cost-saving potential from nanosimilars will likely be substantially higher than the year 2020 estimates, if the increasing number of relevant investigational new drugs (INDs) submitted to the FDA and their anticipated patent expiry dates are also considered (D'Mello et al., 2017) . As early as 2023, patent expiry of ferric carboxymaltose and nanoparticulate paclitaxel alone could provide another EUR 84 million annual saving potential in the EU.
However, at the time of the model development, no new nanosimilars had been approved, and given the uncertainty in regulatory requirements for nanosimilars, manufacturers could consider the investment too risky and be reluctant to develop follow-on products. We argue that if nanosimilars can be approved in a way that provides patients safe and efficacious therapies, market access of these drugs could lead to significant savings. Improved access to treatment may be an additional benefit that has not been quantified and valuated in our model. This further highlights the urgency for well-defined regulatory standards that are appropriate for this unique and expanding class of drugs.
Conclusions
Nanomedicines offer many advantageous properties and stimulate drug innovation and development: increased solubility/bioavailability, better safety and efficacy profile, targeting specific tissues, crossing biological barriers that conventional products cannot bypass, extended drug exposure with a larger therapeutic window, and other unique and impressive features. There are many successful products that belong to this category, and more are being added to that list. And yet, they have not taken over the world. Is that due to lack of awareness and education? Is it because of their complexity or their confusing and non-specific regulatory approval pathways? Or is it both?
It is widely accepted by the scientific community, the pharmaceutical industry and the regulatory bodies that nanomedicines are complex, with specific physicochemical characteristics associated with their nano-size. There is a lot of activity in the form of publications from all sides discussing the topic, including reflection papers by the EMA or draft guidance by the FDA.
Nanomedicines are still evolving and next-generation, more sophisticated drug products will be the norm soon. This will make the future development, evaluation and use of nanomedicines and nanosimilars even more complex. The EMA needs to act now, to be one step ahead and lead the nanomedicine field to the next level, where safe and efficacious products are available for the patient, as was already shown for biosimilars, where regulation started upon approval of the first biologics. It can all start with the establishment of a focused and distinct regulatory pathway for nanosimilars, inspired by the stepwise approach already successfully in use for biosimilars.
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